Adipotide (FTPP) 5mg

Description:

Adipotide, also known as FTPP (Fat Targeted Proapoptotic Peptide), is an experimental peptide drug that has been studied for its potential in the treatment of obesity and certain types of cancer.

The mechanism of action of Adipotide involves targeting and destroying fat cells. It works by binding to the endothelial cells of blood vessels that supply adipose tissue (fat tissue) and triggering their apoptosis, which is a process of programmed cell death. This leads to a reduction in blood supply to the fat cells, causing them to shrink and eventually die.

In animal studies, Adipotide has shown promising results in reducing body weight and body fat in obese animals. It has been observed to induce weight loss, decrease body mass index (BMI), and improve metabolic parameters. However, it’s important to note that Adipotide has not been approved for human use and is still considered an experimental drug.
While Adipotide has primarily been investigated for its potential as an anti-obesity agent, it has also shown some anticancer activity in preclinical studies. By targeting blood vessels that supply tumors, Adipotide may inhibit their growth and induce apoptosis in cancer cells.

Adipotide (FTPP) Research:

Adipotide (FTPP) is a peptide that has been the subject of research primarily in the field of obesity and weight loss. The research on Adipotide aims to understand its mechanism of action, evaluate its effectiveness in promoting weight loss, assess its safety profile, and explore its potential applications. Here are some key areas of research related to Adipotide:

• Preclinical studies: In preclinical studies conducted on animals, Adipotide demonstrated promising results in promoting weight loss and reducing body fat. For example, in a study involving obese rhesus monkeys, treatment with Adipotide resulted in a significant reduction in body weight and body mass index (BMI). The drug specifically targeted visceral fat, leading to a decrease in abdominal circumference. Similar results were observed in mice models of obesity.
• Phase I clinical trial: A phase I clinical trial was conducted to assess the safety and tolerability of Adipotide in humans. The study included overweight and obese individuals. The trial indicated that Adipotide treatment was generally well-tolerated. Participants experienced weight loss, with an average reduction in body weight and BMI. Additionally, improvements in insulin sensitivity were observed.
• Mechanism of action: Researchers have been studying how Adipotide works at a molecular level. It has been found that Adipotide targets and binds to specific receptors on the blood vessels that supply fat cells. This binding triggers apoptosis, or programmed cell death, in the blood vessels, leading to a reduction in blood supply to the fat cells. Without sufficient blood supply, the fat cells shrink and eventually die.
• Weight loss effects: Research has focused on evaluating the weight loss effects of Adipotide in preclinical studies using animal models. These studies have shown that Adipotide treatment leads to significant reductions in body weight, body fat, and visceral fat, particularly in obese animal models. Adipotide has shown the ability to selectively target and reduce fat tissue without affecting lean tissue.
• Metabolic effects: In addition to weight loss, research has also explored the metabolic effects of Adipotide. Studies have indicated improvements in metabolic parameters, such as insulin sensitivity and glucose metabolism, in animal models treated with Adipotide. These findings suggest that Adipotide may have potential benefits beyond weight loss, particularly in addressing metabolic disorders associated with obesity.
• Future applications: Researchers have also explored potential applications of Adipotide beyond obesity treatment. Adipotide’s ability to target and kill blood vessels supplying fat cells has raised interest in its potential use for targeting other conditions, such as certain types of cancer that rely on angiogenesis (the formation of new blood vessels).